Is Novo Nordisk (NVO) Stock A Buy or Sell? – NVO Analysis (May 2026 Update)

Last updated: May 2026. This article was originally published in January 2025 and has been fully updated with current price data, Q1 2026 earnings results, and the latest analyst outlook.

Novo Nordisk A/S is a globally recognized pharmaceutical leader specializing in diabetes care, obesity treatments, and other serious chronic conditions. When we last covered NVO in January 2025, the stock was trading around $85 and had just suffered a sharp decline following disappointing CagriSema trial results. The picture in May 2026 looks significantly different — and not in a comfortable way for those who held.

NVO is currently trading around $45–47, down roughly 47% from where it was when this article was first published, and down approximately 68% from its all-time high of $146 reached in June 2024. Yet beneath that painful decline, there are real signs of a business finding its footing again — and a question worth revisiting: is NVO a buy, a hold, or still a sell?

Track all markets on TradingView

Where NVO Stands in May 2026

The 16-month period since our last update has been a brutal one for NVO shareholders. The stock fell from $85 to a 52-week low of $35.12 earlier in 2026, before partially recovering to the current range of $45–47. That represents a 52-week high of $81.44 and a low of $35.12 — an extraordinary range for a company of this size and reputation.

The causes are well-documented: pricing pressure on Ozempic in the US, increased competition from Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound, the impact of the US “Most Favoured Nations” (MFN) drug pricing policy, and the partial disappointment of the CagriSema clinical program. Add in broader pharmaceutical tariff concerns under the current US administration and the depreciation of the Danish krone against the dollar, and you have a perfect storm that knocked NVO from one of the most beloved growth stocks in the world to a deeply discounted value proposition.

The market cap now sits around $207 billion — still enormous, but roughly a third of its peak valuation.

Q1 2026 Earnings: Mixed Numbers, Positive Surprise

Novo Nordisk reported Q1 2026 results on May 6, 2026, and the headline numbers told a complicated story.

Reported sales reached DKK 96.8 billion, a 32% increase year-over-year — but this was massively inflated by a one-time DKK 26.8 billion reversal of a provision tied to the US 340B Drug Pricing Program. Stripping that out, adjusted sales declined 4% at constant exchange rates, driven by lower realized prices for Ozempic and Wegovy injectable.

Operating profit told a similar story: reported operating profit jumped 65% to DKK 59.6 billion, while adjusted operating profit fell 6% at constant exchange rates to DKK 32.9 billion.

The number that genuinely surprised Wall Street was the Wegovy pill. The oral version of semaglutide, launched in the US on January 5, 2026, generated DKK 2.26 billion ($354 million) in its first full quarter — nearly double analyst estimates of DKK 1.16 billion. The pill reached approximately 207,000 weekly total prescriptions by week 15 since launch, and cumulative prescriptions exceeded 2 million, making it the strongest-ever GLP-1 volume launch in the US by that metric.

CEO Maziar Doustdar called it a “turnaround situation,” noting that Wegovy now holds 65% of all new GLP-1 prescriptions in the US.

As a result of the pill’s outperformance, Novo raised its 2026 full-year guidance, narrowing the outlook to adjusted sales and operating profit declining 4%–12% at constant exchange rates, versus the previous estimate of 5%–13%. Net profit for the quarter came in at DKK 48.6 billion, and EPS of $1.043 beat the consensus estimate of $0.884 by 18%.

Recent Developments Impacting Novo Nordisk Stock

The Wegovy Pill Launch

The FDA approved oral semaglutide 25mg (the Wegovy pill) on December 22, 2025, and Novo launched it in the US on January 5, 2026. The pill’s early performance has been the most encouraging development for the company in over a year. Critically, roughly 80% of Wegovy pill users are GLP-1 treatment-naïve — meaning the pill is pulling in patients who had never tried a GLP-1 drug before, rather than cannibalizing Novo’s own injectable franchise or competing head-to-head with Eli Lilly for existing GLP-1 users. That reframes the competitive narrative meaningfully.

Novo has also received FDA approval for Wegovy HD (7.2mg injectable semaglutide), which was launched in the US on April 7, 2026. In the STEP UP trial, Wegovy HD delivered 20.7% mean weight loss. The company plans to launch the Wegovy pill internationally in select markets in the second half of 2026, pending regulatory approvals.

CagriSema — Another Disappointment, but Not a Disaster

In February 2026, Novo reported headline phase 3 data from its REDEFINE 4 obesity trial showing that CagriSema delivered 23% weight loss at 84 weeks — an impressive absolute result, but one that failed to meet the primary endpoint of non-inferiority versus Eli Lilly’s tirzepatide (which achieved greater weight loss). This was the second time CagriSema missed high expectations, following the original disappointing trial in late 2024.

However, there is nuance here. CagriSema did outperform semaglutide alone in a separate diabetes trial (REIMAGINE 2), showing it as a meaningful step forward in the GLP-1/amylin combination class. Novo continues to pursue the drug for obesity and diabetes labels, and a potential 2027 launch remains in the planning.

Ozempic Pricing Pressure

CFO Karsten Knudsen confirmed on the Q1 2026 earnings call that Ozempic US pricing continues to erode at 10–15% annually — the same trajectory as 2025. Combined with the impact of the MFN drug pricing agreement and reduced obesity medication coverage in Medicaid, US Operations adjusted sales declined 11% at constant exchange rates in Q1. This is the single biggest headwind to Novo’s near-term financials.

Competitive Landscape in 2026

Novo faces a more crowded competitive field in 2026 than at any point since Ozempic’s launch. Eli Lilly’s Mounjaro and Zepbound posted 125% and 80% sales growth respectively in Q1 2026 — a stark contrast to Novo’s declining US revenues. Pfizer, AstraZeneca, and a wave of biotech startups including Kailera Therapeutics are all developing next-generation obesity drugs. Oral GLP-1 entrants from multiple companies are expected to intensify competition in the pill segment, where the Wegovy pill currently leads.

The semaglutide compound patent is also facing expiry in certain international markets, which adds a biosimilar competition risk to Novo’s International Operations over the medium term.

Is Novo Nordisk a Long-Term Investment?

Despite the severe stock decline, the long-term investment case for Novo Nordisk remains credible — though it is no longer the straightforward growth story it appeared to be in 2023 and early 2024.

The structural tailwind is real: global obesity rates continue to climb, and GLP-1 drugs are now established as the most effective pharmacological treatment for weight loss at scale. Novo is serving over 45 million patients globally with its obesity and diabetes therapies, and the market is still in its early innings internationally.

The Wegovy pill’s early success is particularly important for the long-term case. An oral GLP-1 that can reach treatment-naïve patients without the barrier of injection is a genuinely larger addressable market than the injectable-only world. If the pill continues to scale domestically and launches successfully abroad, it has the potential to reignite volume-driven revenue growth even as injectable pricing erodes.

The pipeline also holds promise beyond the current approved products. Zenagamtide (a next-generation amylin agonist) and etavopivat (which met both co-primary endpoints in the HIBISCUS phase 3 sickle cell trial in Q1 2026) represent meaningful diversification beyond the GLP-1 franchise.

On shareholder returns, Novo remains committed: nearly DKK 38 billion was returned via dividends and buybacks in Q1 2026 alone. The dividend yield currently stands at approximately 3.6%, providing income while investors wait for the growth narrative to re-establish itself. The company has authorized a new share buyback of up to DKK 15 billion.

The bear case, however, is also legitimate: a company that derives the vast majority of its revenue from a handful of drugs in one therapeutic area, faces pricing headwinds from both the market and policy, and is losing share to a stronger competitor in its core obesity market, is a very different investment proposition than the one investors paid a premium for in 2024.

NVO Technical Analysis — May 2026

NVO’s stock has been in a prolonged downtrend since its June 2024 all-time high of $146. The 52-week range of $35.12–$81.44 illustrates the scale of the correction. The stock found a floor around $35 in early 2026 and has staged a partial recovery, currently trading in the $45–47 zone.

Key levels to watch:

• $50 — a psychologically important round number and near-term resistance. A sustained break above this level would signal early recovery momentum.
• $40–42 — near-term support, where the stock found buyers in early 2026. A break below would re-test the 52-week low zone.
• $35 — the 52-week low and the line in the sand for long-term bulls. A break below would signal a more sustained structural decline.

The Q1 2026 earnings report on May 6 sent NVO shares up roughly 7% in Copenhagen trading, which is an encouraging signal. Whether that momentum is sustained depends largely on whether the Wegovy pill trajectory continues to outperform and whether management can demonstrate that the adjusted sales decline is bottoming out.

Analyst Ratings and Price Targets

Analyst sentiment on NVO is mixed but tilts slightly positive, reflecting uncertainty about near-term headwinds versus long-term potential:

• Consensus rating: Hold/Moderate Buy (depending on aggregator)
• Average price target: $51–$65 (Benzinga consensus: $85 from 16 analysts including a range from Goldman Sachs at $41 to Cantor Fitzgerald at $160)
• Implied upside from current price (~$46): approximately 10–40% depending on the target used
• Citi: Raised price target to DKK 290 (from DKK 275) following Q1 results
• TD Cowen: Reiterated Hold with a $42 price target
• Bernstein: Sticks to a Sell rating
• TipRanks consensus: Stock flagged as currently undervalued

The wide dispersion in price targets ($41 to $160) reflects genuine disagreement about how quickly pricing headwinds will stabilize, how successfully the Wegovy pill can scale, and whether CagriSema can ultimately contribute meaningfully to revenue.

How to Trade Novo Nordisk Shares

Trading Novo Nordisk shares can be done in two primary ways.

The first is buying physical shares via a brokerage firm with access to the NYSE (where NVO trades as an ADR) or the Nasdaq Copenhagen exchange (where Novo Nordisk B shares trade). This gives you full ownership rights including dividend entitlement.

Alternatively, you can trade NVO through a Contract for Difference (CFD). A CFD lets you speculate on Novo Nordisk’s price movements — both up and down — without owning the underlying shares, and allows you to apply leverage. This is suitable for shorter-term traders looking to capitalize on volatility, but carries significantly higher risk. See our overview of CFD trading for more detail on how these instruments work.

Conclusion: Buy, Hold, or Sell?

NVO is a more interesting stock today than it was when we last wrote about it at $85 in January 2025 — not because things have gotten better, but because the stock has fallen so far that the risk/reward is meaningfully different.

For long-term investors, the current price around $45–47 represents a significant discount to the company’s intrinsic earnings power, assuming the Wegovy pill continues to scale and pricing pressure eventually stabilizes. The dividend yield of ~3.6%, the ongoing buyback program, and the pipeline all support a patient holder’s case. If you believe global GLP-1 adoption is in its early stages — and the data suggests it is — Novo remains one of the two dominant players in that space.

For short-term traders, the stock is in a fragile recovery. The gap between $47 and $50 is the immediate test. The next catalyst is the Q2 2026 earnings report, due August 6, 2026, which will show whether the Wegovy pill maintained its early momentum and whether the adjusted sales decline is narrowing.

The risk factors are real and should not be minimized: Eli Lilly continues to outperform, the MFN pricing policy creates a structural headwind on US margins, CagriSema has twice disappointed, and semaglutide patent expiries are approaching in international markets.

Overall verdict: NVO is a cautious Hold with a long-term Buy case emerging at current levels — but only for investors with a multi-year time horizon and tolerance for continued near-term volatility. It is not the momentum story it was in 2023–2024, but at $45, it may be the value story of 2026–2027.

Disclaimer: This article is for educational and informational purposes only and should not be considered professional financial advice. All investments involve risk. Always perform your own research and consult a qualified financial advisor before making investment decisions.